{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_references_@count in root_references_@count (approximate match)
Status:
Investigational
Source:
INN:alomfilimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00654966: Phase 2 Interventional Completed Heart Failure
(2009)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04563923: Phase 2 Interventional Completed Bullous Pemphigoid
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04097821: Phase 1/Phase 2 Interventional Completed Myelofibrosis
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01405196: Phase 2 Interventional Completed Lupus Erythematosus, Systemic
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03188666: Phase 2 Interventional Completed Fibrodysplasia Ossificans Progressiva
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:gruticibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03846453: Phase 3 Interventional Completed Dry Eye
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01042379: Phase 2 Interventional Recruiting Breast Neoplasms
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02290951: Phase 1 Interventional Active, not recruiting Non-Hodgkin Lymphoma
(2015)
Source URL:
Class:
PROTEIN